PM8002 in the Treatment of Patients With Advanced Solid Tumors

Inclusion Criteria:

1. Voluntary participation in clinical study; fully understand the study and signinformed consent voluntarily; willing to follow and able to complete all testprocedures;

2. Male or female aged 18 to 75 years;

3. Patients with malignant tumor confirmed by histology or cytology;

4. The toxicity of previous anti-tumor therapy has not been alleviated；

5. Adequate organ function；

6. ECOG score was 0-1;

7. Expected survival >=12 weeks;

8. According to RECIST 1.1 criteria, at least 1 measurable lesion that has not beenpreviously treated locally.

Exclusion Criteria:

1. History of severe allergic disease, severe allergy to drugs or known allergy to anycomponent of the drug in this study;

2. Evidence of major coagulopathy or other obvious risk of bleeding;

3. Patients are experiencing a clear interstitial lung disease or non-infectiouspneumonia, unless it is caused by local radiotherapy;

4. Patients with uncontrolled brain metastases should be excluded from this clinicaltrial;

5. Patients ever experienced other active malignant tumors within 5 years prior to thestudy treatment;

6. Prior allogeneic organ transplantation or allogeneic hematopoietic stem celltransplantation;

7. Known history of alcohol abuse, psychotropic drug abuse or drug abuse;

8. Syphilis antibody positive;

9. Patients with active tuberculosis (TB) are excluded;

10. Pregnant or lactating women;

11. Other conditions lead to inappropriate to participate in this study as judged by theinvestigator.